Amgen Reports Second Quarter 2019 Financial Results Read more about Amgen Reports Second Quarter 2019 Financial Results
Amgen Controls 98% Of The Shares In Nuevolution After The End Of The Extended Acceptance Period Read more about Amgen Controls 98% Of The Shares In Nuevolution After The End Of The Extended Acceptance Period
Amgen Announces Webcast Of 2019 Second Quarter Financial Results Read more about Amgen Announces Webcast Of 2019 Second Quarter Financial Results
Amgen And Allergan's MVASI™ (bevacizumab-awwb) And KANJINTI™ (trastuzumab-anns) Now Available In The United States Read more about Amgen And Allergan's MVASI™ (bevacizumab-awwb) And KANJINTI™ (trastuzumab-anns) Now Available In The United States
Amgen, Novartis And Banner Alzheimer's Institute Discontinue Clinical Research Program With BACE Inhibitor CNP520 For Alzheimer's Prevention Read more about Amgen, Novartis And Banner Alzheimer's Institute Discontinue Clinical Research Program With BACE Inhibitor CNP520 For Alzheimer's Prevention
Amgen Announces The Outcome Of The Recommended Public Cash Offer To The Shareholders Of Nuevolution, Declares The Offer Unconditional And Completes The Offer Read more about Amgen Announces The Outcome Of The Recommended Public Cash Offer To The Shareholders Of Nuevolution, Declares The Offer Unconditional And Completes The Offer
Amgen and UCB Provide Regulatory Update on Status of EVENITY™ (romosozumab) in the EU Read more about Amgen and UCB Provide Regulatory Update on Status of EVENITY™ (romosozumab) in the EU
Amgen Showcases Oncology Pipeline At ASCO 2019 Read more about Amgen Showcases Oncology Pipeline At ASCO 2019
Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019 Read more about Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019
FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab) Read more about FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
